Compare Five Below Inc (FIVE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Five Below Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Five Below Inc trades at $214.73 (market cap $11.55B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.6× Five Below Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Five Below Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Five Below Inc for 46 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| FIVE | REGN | |
|---|---|---|
Market Cap | $11.55B | $76.14B |
Volume | 1,120,554 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $262.72 | $852.03 |
52-Week Low | $138.49 | $557.73 |
Typical Hold Time | 46 Days | 107 Days |
Enterprise Value | $12.40B | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Five Below (FIVE) trades at $214.73, up 5.14% with strong technical support at $207-$209. The company shows robust fundamentals with revenue growth from $3.6B to $3.9B (2024-2025) and consistent earnings beats. Analyst consensus is strongly bullish with a $298.44 price target, supported by recent board appointments and a $600M buyback program announced in September 2026.
FIVE presents a compelling growth opportunity with projected 2026 revenue of $5.3B and net income of $619M. However, execution risks remain as the stock trades at premium valuations (P/E 18.81, P/S 2.19) amid competitive retail pressures and consumer spending sensitivity to inflation.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
